TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston

TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston
October 16, 2019 theraaixadsf418

We are proud partners for the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) which will take place on November 18-20th in Boston.

Keynote speakers for the event include Glenn Rosen from Coherus Biosciences, Lisa Hazelwood from Abbvie, Matthew Breyer from Janssen, Rozsa Schlenker-Herceg from Boehringer-Ingelheim, Tim Johnson from UCB and Zoe Johnson from iOnctura.

The event offers 3 days of in-depth cutting-edge case studies and high calibre industry and academic discussions across all fibrotic conditions. This year, the event anticipates over 100 anti-fibrotic drug developers to be in attendance.

On Tuesday 19th November, TherapeutAix’ Darcey Black will deliver a presentation on ‘Building a platform of evidence that will lead to clinical and partnering success in fibrotic disease’. This will include looking at the future clinical landscape of fibrotic disease and the opportunity to improve translation via the use of biomarkers.

Darcey and his TherapeutAix colleague, Simon Cruwys, look forward to connecting with like-minded peers who are in the drug development for fibrotic disease field and meeting up with pre-existing contacts and clients.

To see the full programme of the event, please click here.

If you would like to arrange a meeting at the AFDD summit please don’t hesitate to get in touch with us.

Sign up to our newsletter to get updated regarding the latest events we are attending and company updates.